Biomea Fusion Pursues Unparalleled Opportunity to Address Root Cause of Diabetes

Biopharmaceutical company, Biomea Fusion (Nasdaq: BMEA) has reported positive initial response data from two type 1 diabetes patients treated with BMF-219 in the company’s ongoing Phase 2 clinical trial. Both patients showed improvement in measures of beta-cell function after four weeks of dosing with BMF-219.

More than 37 million people in the US have diabetes, including 35 million with type 2 diabetes and approximately two million with type 1 diabetes.

Dr. Tom Elliott, Medical Director of BC Diabetes, Clinical Associate Professor of Medicine at the University of British Columbia Division of Endocrinology, and a key investigator in the type 1 COVALENT-112 study commented, “In my 32 years of practice as an endocrinologist I have never before seen a type 1 diabetes agent achieve such immediate increases in C-peptide secretion.  We need longer-term follow up in a greater number of patients to validate these early signals, but I am very excited for the potential BMF-219 may provide for people with type 1 and type 2 diabetes. This is an unparalleled opportunity to address the root cause of diabetes.”

Biomea Fusion’s trial is a randomized, placebo-controlled, double-blind Phase II study of 150 patients designed to examine the safety, efficacy, and durability of BMF-219 in adults diagnosed with type 1 diabetes.

Diabetes is a chronic health condition that can cause serious health problems and damage vital organs.

About Biomea Fusion

Biomea Fusion is a clinical stage biopharmaceutical company focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional non-covalent drugs, including greater target selectivity, lower drug exposure, and the ability to drive a deeper, more durable response.

We are utilizing our proprietary FUSION™ System to discover, design and develop a pipeline of next-generation covalent-binding small molecule medicines designed to maximize clinical benefit for patients. We aim to have an outsized impact on the treatment of disease for the patients we serve. We aim to cure.

Visit us at biomeafusion.com and follow us on LinkedIn, Twitter and Facebook.

Share This Article

 

About the Author

Biomea Fusion Pursues Unparalleled Opportunity to Address Root Cause of Diabetes

Catie Corcoran

Biotech Editor